The Effect of Stigma on Family Planning and HIV Pre-exposure Prophylaxis Decisions of Young Women Accessing Post-Abortion Care in Kenya
AbstractAdolescent girls and young women (AGYW) in Eastern and Southern Africa face parallel epidemics of unintended pregnancy and HIV. Their sexual health decisions are often dominated by intersecting stigmas. In an implementation science project integrating delivery of daily, oral pre-exposure prophylaxis (PrEP) for HIV prevention into 14 post-abortion care (PAC) clinics in Kenya, we enrolled a subset of PrEP initiating AGYW (aged 15 to 30 years) into a research cohort. Utilizing log binomial models, we estimated the effect of PrEP stigma on PrEP continuation (measured via self-report and urine assay for tenofovir) and...
Source: AIDS and Behavior - March 7, 2024 Category: Infectious Diseases Source Type: research
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States
CONCLUSIONS: The 90-day TFV ring was well-tolerated, acceptable and exceeded target cervical tissue concentrations through day 56, but declined thereafter. Additional studies are needed to characterize the higher release from TFV rings in some participants and the optimal duration of use.PMID:38444118 | DOI:10.1002/jia2.26223 (Source: Herpes)
Source: Herpes - March 6, 2024 Category: Infectious Diseases Authors: Albert Y Liu Holly Gundacker Barbra Richardson Beatrice A Chen Craig Hoesley Ariane van der Straten Amanda Brown May Beamer Jennifer Robinson Cindy E Jacobson Rachel Scheckter Katherine Bunge Jill Schwartz Andrea Thurman Jeanna M Piper Mark A Marzinke MTN Source Type: research
Effect of differentiated direct-to-pharmacy PrEP refill visits supported with client HIV self-testing on clinic visit time and early PrEP continuation
CONCLUSIONS: A client-centred PrEP delivery approach with direct-to-pharmacy PrEP refill visits plus client HIVST significantly reduced clinic visit time by more than one-third and improved PrEP continuation in public health HIV clinics in Kenya.PMID:38446643 | DOI:10.1002/jia2.26222 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - March 6, 2024 Category: Infectious Diseases Authors: Kidist Belay Zewdie Kenneth Ngure Margaret Mwangi Dominic Mwangi Simon Maina Lydia Etyang Gakuo Maina Vallery Ogello Emmah Owidi Nelly R Mugo Jared M Baeten Kenneth K Mugwanya Source Type: research
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States
CONCLUSIONS: The 90-day TFV ring was well-tolerated, acceptable and exceeded target cervical tissue concentrations through day 56, but declined thereafter. Additional studies are needed to characterize the higher release from TFV rings in some participants and the optimal duration of use.PMID:38444118 | DOI:10.1002/jia2.26223 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - March 6, 2024 Category: Infectious Diseases Authors: Albert Y Liu Holly Gundacker Barbra Richardson Beatrice A Chen Craig Hoesley Ariane van der Straten Amanda Brown May Beamer Jennifer Robinson Cindy E Jacobson Rachel Scheckter Katherine Bunge Jill Schwartz Andrea Thurman Jeanna M Piper Mark A Marzinke MTN Source Type: research
What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?
CONCLUSIONS: Long-acting PrEP holds promise for reducing HIV incidence, but its implications for the HBV epidemic, particularly in sub-Saharan Africa, should not be overlooked.PMID:38444112 | DOI:10.1002/jia2.26218 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - March 6, 2024 Category: Infectious Diseases Authors: Amir M Mohareb Menan G érard Kouamé Marcellin Nouaman Arthur Y Kim Joseph Larmarange Anne M Neilan Karine Lacombe Kenneth A Freedberg Anders Boyd Patrick Coffie Emily P Hyle Source Type: research
Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabina/tenofovir-alafenamide among people with HIV
CONCLUSION: In our study patients had a high persistence. Patients on DTG/3TC treatment were more persistent compared to BIC/FTC/TAF, although BIC/FTC/TAF have worse baseline characteristics. The main reason for discontinuation of BIC/FTC/TAF was tolerability/toxicity.PMID:38448360 | DOI:10.1016/j.farma.2024.02.002 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - March 6, 2024 Category: Drugs & Pharmacology Authors: Lorena Mart ín-Zaragoza Javier S ánchez-Rubio-Ferrández Alberto Onteniente-Gonz ález Marcos G ómez-Bermejo Sergio Julio Rodr íguez-Álvarez Alfonso Monereo-Alonso Teresa Molina-Garc ía Source Type: research
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States
CONCLUSIONS: The 90-day TFV ring was well-tolerated, acceptable and exceeded target cervical tissue concentrations through day 56, but declined thereafter. Additional studies are needed to characterize the higher release from TFV rings in some participants and the optimal duration of use.PMID:38444118 | DOI:10.1002/jia2.26223 (Source: Herpes)
Source: Herpes - March 6, 2024 Category: Infectious Diseases Authors: Albert Y Liu Holly Gundacker Barbra Richardson Beatrice A Chen Craig Hoesley Ariane van der Straten Amanda Brown May Beamer Jennifer Robinson Cindy E Jacobson Rachel Scheckter Katherine Bunge Jill Schwartz Andrea Thurman Jeanna M Piper Mark A Marzinke MTN Source Type: research
Effect of differentiated direct-to-pharmacy PrEP refill visits supported with client HIV self-testing on clinic visit time and early PrEP continuation
CONCLUSIONS: A client-centred PrEP delivery approach with direct-to-pharmacy PrEP refill visits plus client HIVST significantly reduced clinic visit time by more than one-third and improved PrEP continuation in public health HIV clinics in Kenya.PMID:38446643 | DOI:10.1002/jia2.26222 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - March 6, 2024 Category: Infectious Diseases Authors: Kidist Belay Zewdie Kenneth Ngure Margaret Mwangi Dominic Mwangi Simon Maina Lydia Etyang Gakuo Maina Vallery Ogello Emmah Owidi Nelly R Mugo Jared M Baeten Kenneth K Mugwanya Source Type: research
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States
CONCLUSIONS: The 90-day TFV ring was well-tolerated, acceptable and exceeded target cervical tissue concentrations through day 56, but declined thereafter. Additional studies are needed to characterize the higher release from TFV rings in some participants and the optimal duration of use.PMID:38444118 | DOI:10.1002/jia2.26223 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - March 6, 2024 Category: Infectious Diseases Authors: Albert Y Liu Holly Gundacker Barbra Richardson Beatrice A Chen Craig Hoesley Ariane van der Straten Amanda Brown May Beamer Jennifer Robinson Cindy E Jacobson Rachel Scheckter Katherine Bunge Jill Schwartz Andrea Thurman Jeanna M Piper Mark A Marzinke MTN Source Type: research
What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?
CONCLUSIONS: Long-acting PrEP holds promise for reducing HIV incidence, but its implications for the HBV epidemic, particularly in sub-Saharan Africa, should not be overlooked.PMID:38444112 | DOI:10.1002/jia2.26218 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - March 6, 2024 Category: Infectious Diseases Authors: Amir M Mohareb Menan G érard Kouamé Marcellin Nouaman Arthur Y Kim Joseph Larmarange Anne M Neilan Karine Lacombe Kenneth A Freedberg Anders Boyd Patrick Coffie Emily P Hyle Source Type: research
Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabina/tenofovir-alafenamide among people with HIV
CONCLUSION: In our study patients had a high persistence. Patients on DTG/3TC treatment were more persistent compared to BIC/FTC/TAF, although BIC/FTC/TAF have worse baseline characteristics. The main reason for discontinuation of BIC/FTC/TAF was tolerability/toxicity.PMID:38448360 | DOI:10.1016/j.farma.2024.02.002 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - March 6, 2024 Category: Drugs & Pharmacology Authors: Lorena Mart ín-Zaragoza Javier S ánchez-Rubio-Ferrández Alberto Onteniente-Gonz ález Marcos G ómez-Bermejo Sergio Julio Rodr íguez-Álvarez Alfonso Monereo-Alonso Teresa Molina-Garc ía Source Type: research
Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabina/tenofovir-alafenamide among people with HIV
CONCLUSION: In our study patients had a high persistence. Patients on DTG/3TC treatment were more persistent compared to BIC/FTC/TAF, although BIC/FTC/TAF have worse baseline characteristics. The main reason for discontinuation of BIC/FTC/TAF was tolerability/toxicity.PMID:38448360 | DOI:10.1016/j.farma.2024.02.002 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - March 6, 2024 Category: Drugs & Pharmacology Authors: Lorena Mart ín-Zaragoza Javier S ánchez-Rubio-Ferrández Alberto Onteniente-Gonz ález Marcos G ómez-Bermejo Sergio Julio Rodr íguez-Álvarez Alfonso Monereo-Alonso Teresa Molina-Garc ía Source Type: research
Viruses, Vol. 16, Pages 405: Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies
an
Jörg Sievers
In GEMINI-1/-2, dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in achieving viral suppression (viral load [VL] < 50 copies/mL) in treatment-naive adults. Abbott’s RealTime HIV-1 assay provides quantitative VL (40–10,000,000 copies/mL) and qualitative target detected or target not detected (TND) for VL < 40 copies/mL. This post hoc analysis assessed very-low-level viremia and “blips” through Week 144. Proportions with VL < 40 copies/mL and TND are...
Source: Viruses - March 6, 2024 Category: Virology Authors: Mark Underwood Rimgaile Urbaityte Ruolan Wang Joe Horton James Oyee Brian Wynne Dainielle Fox Bryn Jones Choy Man J örg Sievers Tags: Communication Source Type: research
Prevalence of HIV Drug Resistance Mutations among Treatment-Naive People Living with HIV in a Tertiary Care Center in India
Am J Trop Med Hyg. 2024 Mar 5:tpmd230026. doi: 10.4269/ajtmh.23-0026. Online ahead of print.ABSTRACTIndia has the third-largest number of people living with HIV (PLHIV) in the world. A national program provides free access to standard uniform antiretroviral therapy. However, the program is not monitored by comprehensive drug resistance surveys. The aim of this study was to determine the prevalence of HIV drug resistance mutations (DRMs) among treatment-naive PLHIV in a large antiretroviral treatment center of the national program. This cross-sectional study was done in 2017 and involved 200 consecutive treatment-naive PLHI...
Source: The American Journal of Tropical Medicine and Hygiene - March 5, 2024 Category: Tropical Medicine Authors: Shweta Srivastva Jaya Chakravarty Anurag Kumar Kushwaha Source Type: research
Prevalence of HIV Drug Resistance Mutations among Treatment-Naive People Living with HIV in a Tertiary Care Center in India
Am J Trop Med Hyg. 2024 Mar 5:tpmd230026. doi: 10.4269/ajtmh.23-0026. Online ahead of print.ABSTRACTIndia has the third-largest number of people living with HIV (PLHIV) in the world. A national program provides free access to standard uniform antiretroviral therapy. However, the program is not monitored by comprehensive drug resistance surveys. The aim of this study was to determine the prevalence of HIV drug resistance mutations (DRMs) among treatment-naive PLHIV in a large antiretroviral treatment center of the national program. This cross-sectional study was done in 2017 and involved 200 consecutive treatment-naive PLHI...
Source: Am J Trop Med Hyg - March 5, 2024 Category: Infectious Diseases Authors: Shweta Srivastva Jaya Chakravarty Anurag Kumar Kushwaha Source Type: research
